BR112013022164A2 - peptídeo, vacina, e, anticorpo - Google Patents

peptídeo, vacina, e, anticorpo

Info

Publication number
BR112013022164A2
BR112013022164A2 BR112013022164A BR112013022164A BR112013022164A2 BR 112013022164 A2 BR112013022164 A2 BR 112013022164A2 BR 112013022164 A BR112013022164 A BR 112013022164A BR 112013022164 A BR112013022164 A BR 112013022164A BR 112013022164 A2 BR112013022164 A2 BR 112013022164A2
Authority
BR
Brazil
Prior art keywords
antibody
peptide vaccine
vaccine
peptide
Prior art date
Application number
BR112013022164A
Other languages
English (en)
Inventor
Schuh Birgit
Juno Claudia
Bilcikova Erika
Gebhart Mathias
Linzmayer-Hirt Pola
Brunner Sylvia
Original Assignee
Affiris Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris Ag filed Critical Affiris Ag
Publication of BR112013022164A2 publication Critical patent/BR112013022164A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112013022164A 2011-06-10 2012-06-11 peptídeo, vacina, e, anticorpo BR112013022164A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11169481A EP2532359A1 (en) 2011-06-10 2011-06-10 CETP fragments
PCT/EP2012/061038 WO2012168486A1 (en) 2011-06-10 2012-06-11 Cetp fragments

Publications (1)

Publication Number Publication Date
BR112013022164A2 true BR112013022164A2 (pt) 2018-06-26

Family

ID=44514130

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013022164A BR112013022164A2 (pt) 2011-06-10 2012-06-11 peptídeo, vacina, e, anticorpo

Country Status (15)

Country Link
US (1) US9085636B2 (pt)
EP (2) EP2532359A1 (pt)
JP (1) JP6336901B2 (pt)
KR (1) KR20140026390A (pt)
CN (1) CN103635204B (pt)
AU (1) AU2012266245B2 (pt)
BR (1) BR112013022164A2 (pt)
CA (1) CA2837767A1 (pt)
DK (1) DK2717908T3 (pt)
ES (1) ES2545458T3 (pt)
IL (1) IL227821A0 (pt)
MX (1) MX2013009521A (pt)
RU (1) RU2014100115A (pt)
SG (1) SG194425A1 (pt)
WO (1) WO2012168486A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR111760A1 (es) * 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011782A1 (en) 1991-12-19 1993-06-24 Southwest Foundation For Biomedical Research Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments
JPH09501186A (ja) 1994-11-12 1997-02-04 株式会社エルジ化学 コレステリルエステル運搬蛋白質阻害ペプチドおよびこれを含む動脈硬化症のための予防および治療剤
US6410022B1 (en) 1995-05-01 2002-06-25 Avant Immunotherapeutics, Inc. Modulation of cholesteryl ester transfer protein (CETP) activity
JP3580948B2 (ja) * 1995-05-02 2004-10-27 日本たばこ産業株式会社 ヒト由来ｃｅｔｐに反応性を有するモノクローナル抗体及びヒト由来ｃｅｔｐの定量方法
AU2002325827A1 (en) * 2001-06-07 2002-12-16 Genfit Compositions and methods for detecting or regulating cholesteryl ester transfer protein
AT500835B1 (de) 2004-09-13 2007-12-15 Affiris Forschungs & Entwicklungs Gmbh Cholinestertransport-protein-mimotop als atherosklerose-medikament
US20060276400A1 (en) 2005-06-06 2006-12-07 Hedy Adari Modulation of cholesteryl ester transfer protein (CETP) activity
US20100233177A1 (en) 2007-04-13 2010-09-16 David Langdon Yowe Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9)
AT505574B1 (de) 2007-08-10 2009-09-15 Affiris Forschungs & Entwicklungs Gmbh Mimotope zur behandlung von atherosklerose
AT507604A1 (de) 2008-11-19 2010-06-15 Affiris Forschungs & Entwicklungs Gmbh Behandlung von atherosklerose
NZ620441A (en) 2009-09-03 2015-08-28 Pfizer Vaccines Llc Pcsk9 vaccine

Also Published As

Publication number Publication date
SG194425A1 (en) 2013-12-30
JP6336901B2 (ja) 2018-06-06
MX2013009521A (es) 2013-10-01
AU2012266245A1 (en) 2013-08-29
WO2012168486A1 (en) 2012-12-13
CN103635204B (zh) 2016-03-30
US20140147456A1 (en) 2014-05-29
ES2545458T3 (es) 2015-09-11
AU2012266245B2 (en) 2017-02-02
EP2532359A1 (en) 2012-12-12
CA2837767A1 (en) 2012-12-13
US9085636B2 (en) 2015-07-21
RU2014100115A (ru) 2015-07-20
NZ613913A (en) 2015-07-31
DK2717908T3 (en) 2015-08-03
EP2717908B1 (en) 2015-07-22
EP2717908A1 (en) 2014-04-16
JP2014519512A (ja) 2014-08-14
KR20140026390A (ko) 2014-03-05
IL227821A0 (en) 2013-09-30
CN103635204A (zh) 2014-03-12

Similar Documents

Publication Publication Date Title
LTC2635601I2 (lt) Antikūnai prieš il-23
BR112014012137A2 (pt) anticorpos anti-fgfr2 e suas utilizações
CO7020851A2 (es) Proteínas y péptidos modificados
CO6811812A2 (es) Anticuerpo anti-b7-h3
CO7020871A2 (es) Anticuerpos anti-il-36r
DK2844286T3 (da) Lyofiliserede og vandige anti-CD40-antistofformuleringer
DK3275892T3 (da) Præfusions-rsv-f-antigener
DK2914291T3 (da) Anti-komplement-c1s-antistoffer og anvendelser deraf
DK2794654T3 (da) Anti-phf-tau-antistoffer og deres anvendelser
DK2683406T3 (da) Anti-cd40-antistoffer og anvendelser deraf
DK2934584T3 (da) Anti-gdf15-antistoffer
BR112014004902A2 (pt) peptídeos
BR112015003838A2 (pt) formulações de anticorpo e proteína
BR112012030311A2 (pt) anticorpo
BR112014009050A2 (pt) pirrolbenzodiazepinas e conjugados destas
DK2850101T3 (da) Anti-FcRn-antistoffer
CR20140127A (es) Anticuerpo anti-abtcr
DK2785375T3 (da) Anti-pd-l1-antistoffer og anvendelser deraf
CO7020866A2 (es) Péptidos terapéuticos
BR112014024373A2 (pt) anticorpos regulados por protease
DK3321287T3 (da) Fusionsproteiner og kombinationsvacciner
CO6900146A2 (es) Imidazopiridazinas sustituidas con amino
BR112013020383A2 (pt) formulações liofilizadas.
CO6801637A2 (es) Formulaciones de anticuerpos
DK2668210T3 (da) Anti-kit antistoffer og anvendelser deraf

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2478 DE 03-07-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]